Surveillance for Adverse Events After COVID-19 mRNA Vaccination

2021632 citationsJournal Articlebronze Open Access

Authors

Nicola P. Klein · Kaiser Permanente

Ned Lewis · Kaiser Permanente

Kristin Goddard · Kaiser Permanente

Bruce Fireman · Kaiser Permanente

Ousseny Zerbo · Kaiser Permanente

Kayla E. Hanson · Marshfield Clinic

James G. Donahue ·

Abstract

In interim analyses of surveillance of mRNA COVID-19 vaccines, incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination. While CIs were wide for many outcomes, surveillance is ongoing.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Vaccine Coverage and Hesitancy Heparin-Induced Thrombocytopenia and Thrombosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 326, Issue 14, pp. 1390-1390

DOI: 10.1001/jama.2021.15072

Field-Weighted Citation Impact: 36.35